Literature DB >> 20542007

Structure of the human mTOR complex I and its implications for rapamycin inhibition.

Calvin K Yip1, Kazuyoshi Murata, Thomas Walz, David M Sabatini, Seong A Kang.   

Abstract

The mammalian target of rapamycin complex 1 (mTORC1) regulates cell growth in response to the nutrient and energy status of the cell, and its deregulation is common in human cancers. Little is known about the overall architecture and subunit organization of this essential signaling complex. We have determined the three-dimensional (3D) structure of the fully assembled human mTORC1 by cryo-electron microscopy (cryo-EM). Our analyses reveal that mTORC1 is an obligate dimer with an overall rhomboid shape and a central cavity. The dimeric interfaces are formed by interlocking interactions between the mTOR and raptor subunits. Extended incubation with FKBP12-rapamycin compromises the structural integrity of mTORC1 in a stepwise manner, leading us to propose a model in which rapamycin inhibits mTORC1-mediated phosphorylation of 4E-BP1 and S6K1 through different mechanisms. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20542007      PMCID: PMC2887672          DOI: 10.1016/j.molcel.2010.05.017

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  32 in total

1.  Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action.

Authors:  Kenta Hara; Yoshiko Maruki; Xiaomeng Long; Ken-ichi Yoshino; Noriko Oshiro; Sujuti Hidayat; Chiharu Tokunaga; Joseph Avruch; Kazuyoshi Yonezawa
Journal:  Cell       Date:  2002-07-26       Impact factor: 41.582

Review 2.  Regulation of cap-dependent translation by eIF4E inhibitory proteins.

Authors:  Joel D Richter; Nahum Sonenberg
Journal:  Nature       Date:  2005-02-03       Impact factor: 49.962

3.  Structure of TOR and its complex with KOG1.

Authors:  Alessandra Adami; Begoña García-Alvarez; Ernesto Arias-Palomo; David Barford; Oscar Llorca
Journal:  Mol Cell       Date:  2007-08-03       Impact factor: 17.970

4.  Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation.

Authors:  Andrew Y Choo; Sang-Oh Yoon; Sang Gyun Kim; Philippe P Roux; John Blenis
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-27       Impact factor: 11.205

5.  Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40.

Authors:  Emilie Vander Haar; Seong-Il Lee; Sricharan Bandhakavi; Timothy J Griffin; Do-Hyung Kim
Journal:  Nat Cell Biol       Date:  2007-02-04       Impact factor: 28.824

6.  The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1.

Authors:  Yasemin Sancak; Timothy R Peterson; Yoav D Shaul; Robert A Lindquist; Carson C Thoreen; Liron Bar-Peled; David M Sabatini
Journal:  Science       Date:  2008-05-22       Impact factor: 47.728

7.  Nutrient-dependent multimerization of the mammalian target of rapamycin through the N-terminal HEAT repeat region.

Authors:  Terunao Takahara; Kenta Hara; Kazuyoshi Yonezawa; Hiroyuki Sorimachi; Tatsuya Maeda
Journal:  J Biol Chem       Date:  2006-07-26       Impact factor: 5.157

Review 8.  Growing roles for the mTOR pathway.

Authors:  Dos D Sarbassov; Siraj M Ali; David M Sabatini
Journal:  Curr Opin Cell Biol       Date:  2005-10-13       Impact factor: 8.382

Review 9.  Defining the role of mTOR in cancer.

Authors:  David A Guertin; David M Sabatini
Journal:  Cancer Cell       Date:  2007-07       Impact factor: 31.743

10.  Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.

Authors:  Morris E Feldman; Beth Apsel; Aino Uotila; Robbie Loewith; Zachary A Knight; Davide Ruggero; Kevan M Shokat
Journal:  PLoS Biol       Date:  2009-02-10       Impact factor: 8.029

View more
  199 in total

1.  High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1.

Authors:  Paige Yellen; Mahesh Saqcena; Darin Salloum; Jiangnan Feng; Angela Preda; Limei Xu; Vanessa Rodrik-Outmezguine; David A Foster
Journal:  Cell Cycle       Date:  2011-11-15       Impact factor: 4.534

Review 2.  mTOR signaling in growth control and disease.

Authors:  Mathieu Laplante; David M Sabatini
Journal:  Cell       Date:  2012-04-13       Impact factor: 41.582

Review 3.  Insulin resistance due to nutrient excess: is it a consequence of AMPK downregulation?

Authors:  Asish K Saha; X Julia Xu; Thomas W Balon; Amanda Brandon; Edward W Kraegen; Neil B Ruderman
Journal:  Cell Cycle       Date:  2011-10-15       Impact factor: 4.534

Review 4.  From signal transduction to autophagy of plant cell organelles: lessons from yeast and mammals and plant-specific features.

Authors:  Sigrun Reumann; Olga Voitsekhovskaja; Cathrine Lillo
Journal:  Protoplasma       Date:  2010-08-24       Impact factor: 3.356

Review 5.  Rapamycin-resistant effector T-cell therapy.

Authors:  Daniel H Fowler
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

6.  Genetic analysis of TOR complex gene variation with human longevity: a nested case-control study of American men of Japanese ancestry.

Authors:  Brian J Morris; Timothy A Donlon; Qimei He; John S Grove; Kamal H Masaki; Ayako Elliott; D Craig Willcox; Richard Allsopp; Bradley J Willcox
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2014-03-03       Impact factor: 6.053

7.  Diminished MTORC1-Dependent JNK Activation Underlies the Neurodevelopmental Defects Associated with Lysosomal Dysfunction.

Authors:  Ching-On Wong; Michela Palmieri; Jiaxing Li; Dmitry Akhmedov; Yufang Chao; Geoffrey T Broadhead; Michael X Zhu; Rebecca Berdeaux; Catherine A Collins; Marco Sardiello; Kartik Venkatachalam
Journal:  Cell Rep       Date:  2015-09-17       Impact factor: 9.423

8.  Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome.

Authors:  Suchithra Menon; Christian C Dibble; George Talbott; Gerta Hoxhaj; Alexander J Valvezan; Hidenori Takahashi; Lewis C Cantley; Brendan D Manning
Journal:  Cell       Date:  2014-02-13       Impact factor: 41.582

Review 9.  PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects.

Authors:  Rosalin Mishra; Hima Patel; Samar Alanazi; Mary Kate Kilroy; Joan T Garrett
Journal:  Int J Mol Sci       Date:  2021-03-27       Impact factor: 5.923

Review 10.  What is the impact of immunosuppressive treatment on the post-transplant renal osteopathy?

Authors:  Kristina Blaslov; Lea Katalinic; Petar Kes; Goce Spasovski; Ruzica Smalcelj; Nikolina Basic-Jukic
Journal:  Int Urol Nephrol       Date:  2013-11-12       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.